Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who cares? You asked, I answered. It appears that people on this board have been watching for years, and what they've learned is that they have taken a bath and have been conned by Waggoner. Just think of all the gains they could have had by investing in an index fund or another biotech company these past 3 years. Anybody who is interested in PMCB could have held out and made money elsewhere, and then revisited this stock at greatly depressed prices. There's still no reason to buy.
No, not buying. No reason to.
You nailed it. Every prediction on this board..."no way we fall below [pick your number]" goes by the wayside. It baffles me what people are basing these predictions on. It will keep falling unless a timeline is issued by Waggoner. Absolutely no reason for investors to pile into this stock without a believable timeline.
Welcome to single digits, or as some people on this board refer to it, the 100th buying opportunity in the past 3 years!
Beautiful charts showing the decline in the stock price. To an investor, they mean absolutely nothing but negative momentum.
True, the future looks to be specific therapies targeting activated pathways or immunotherapy, although chemotherapy may synergize with immunotherapy by heightening tumor cells' vulnerability to immunotherapy. Not sure if this effect would be strengthened with CIAB. Also, the dosage of ifosfamide delivered directly to the tumor will be much higher using CIAB...hard to tell if tumors have resistance to ifosfamide if they were being inadequately treated due to dose limitations owing to toxicity of the drug. In any event, PMCB has a lot to prove, and the share price will remain suppressed until a timeline is delivered by Waggner, who seems to be given god-like status on this board by some people despite not doing much to excite the investment community.
I've heard this story before on this board. It will never go below [name a price], and the next day it does go below it.
No timeline means no upward pressure on the share price and a possibility that it goes to single digits.
An excellent summary, bearspread, especially about ongoing trials of other treatments!
I personally know of other treatments for advanced pancreatic cancer making their way through clinical trials.
Why the minute-to-minute crazy fluctuations in the stock price today?
Lack of awareness and lack of experience with the technology. Only a select few have ever been near even a preclinical trial of the technology. Focus in oncology for the past year has been on immunotherapy and how to enhance it. Lots of oncologists are already using immunotherapies.
It's not just the media; this hasn't attracted the attention of oncologists. I attend ASCO every year, and I often attend ASCO GI or ESMO, and in addition to original research, these meetings have lectures entitled "What's new in xxxxx" or "Developments in xxxxxxxx" and not once have I heard CIAB mentioned. The media will pay attention if oncologists ever start talking about the technology.
I'm not on here to talk the stock down or to talk it up. I use it as information exchange, and there's rarely useful information here. The longs make predictions on this message board that never seem to come true. Just like Wagner's timeline. Don't be angry at me because investors had a negative reaction to Tuesday's conference call.
It was a response to another post in which the author sought to identify an orphan drug designation as unique. It's not.
BTW, there are 1,037 products with orphan drug designation since January 2014.
If you've done your due diligence and believe that adding more shares at 0.103 is prudent, then by all means, do so. There are other equally informed people who see no need to add at this level when there's no upward pressure on the stock. Good luck to everybody here!
We have opposing forces on this message board. The people who insist that it can't go lower than 0.11, and then of course it does go lower, and then they are certain it won't go below 0.10, until it does go below 0.10, and so forth. Then there are those who are rooting for it to go to 0.02 or 0.03 as if lack of faith by the investment community is a positive. Investors aren't going to touch this unless there's a good reason to do so, and the conference call earlier this week did nothing to excite them about this company. They're probably well aware that a clinical trial was first promised in Q1 of 2015, and we're 2 years out, so they don't feel any urgency to add this to their portfolio. Hence, the price won't go higher.
That conference call definitely stopped the upward momentum of the stock price. Even people who are interested in this stock know that there's no rush to get in without anything new to report. Expect pps to go lower.
You're correct. Without a positive catalyst, expect a slow drop in the pps. No reason for investors to pile into PMCB.
No, there is no catalyst soon that will drive the share price higher. If somebody is interested in this company, there won't be harm in waiting.
No, it's not. But people on this message board were predicting a "pop" after the cc. We're seeing a backwards pop. And that's because little news was presented yesterday that translated into a reason to buy.
I don't think that's true. People are not looking to get rich quick; that time has passed. They want to see progress, of which there has been little over the past several years.
Down 15%. On what impetus will the stock price increase later in the week?
No need for a 3-year trial because patients won't be living that long. These are patients with advanced inoperable cancer that has stopped responding to standard of care. A 2- or 3-month gain in overall survival would be a major win.
Time and patience is fine but realize that there's an opportunity cost to it. A person who has been invested in this company for 4 years and has seen no movement or downward movement in the stock price is worse off than the investor who made money for 4 years and is now just getting into the stock, or waiting even longer. Consider that the market over the past 4 years is probably up 30%, and then you can appreciate how patience has been an enemy. Can you tell me that you're better off having held this stock for 4 years than investing somewhere else and getting in on PMCB on February 8, 2017?
Did anybody else lose the audio?
I think it would depend on the drug's mechanism of action.
My point is that other companies have agents that are also making progress in clinical trials. They're moving along while PMCB hasn't yet enrolled a patient.
PMCB can't wait any longer to start its trial. Those studies presented last week were phase 1/1b so even they require larger randomized trials to change standard of care. But those other drugs may be advancing to the next phases quicker than CIAB advances, if PMCB drags its feet.
True, but CIAB is being compared to a regimen that may not be the standard for long in advanced pancreatic cancer.
Not necessarily. For example, cisplatin works on DNA repair deficiencies.
People might also be selling PMCB because gemcitabine and nab-paclitaxel will soon not be the standard of care for advanced pancreatic cancer. I attended the 2017 GI Cancers Symposium last week and some newer strategies look promising, such as adding cisplatin to the regimen, which extended median survival to 16.5 months, and there were two other drugs that looked encouraging in phase 1 trials.
I don't. It's totally baseless like every other prediction on here!
Sold 150,000 shares at 0.13 today. Will look to pick those back up before close.
No doubt on its way to 0.18!
Go PMCB! On its way to 0.17 before close today!
Go PMCB!
Actual funding secured for a clinical trial! A game changer.
First comes the pump
...
...
...
...
Then comes the dump.
If you had waited another day, you could have gotten 600,000 shares. And if you had waited until December, maybe a million.
Down 7% more. Is today another one of those buying opportunities? They're coming fast and furious these days, while the rest of biotech skyrockets.
Hey, but every new day is a new buying opportunity. It doesn't get better than constant losses so one can load up on more shares.